63rd European Renal Association Congress (ERA 2026)

Glasgow, Scotland, UK 03 June 2026 - 06 June 2026

Pooled KARDIA data show effective BP control with add-on zilebesiran

07 Jul 2026 bởi

A pooled analysis of data from the phase II KARDIA 2 and 3 studies shows the blood pressure (BP)-lowering potential of zilebesiran, an investigational, long-acting RNA interference therapeutic, when added to a renin–angiotensin–aldosterone system inhibitor (RAASi) in patients with hypertension (HTN).

07 Jul 2026

Updated ALIGN data boost atrasentan potential in IgAN

18 Jun 2026 bởi

Results from the final analysis of the phase III ALIGN trial continue to support the efficacy and safety of atrasentan for the treatment of IgA nephropathy (IgAN).

18 Jun 2026